Switch to Warfarin and Repeat TEE Before Any Further Cardioversion Attempt
In this 70-year-old patient with ATTR-CA who developed left atrial sludge on rivaroxaban, I recommend switching anticoagulation to warfarin (INR 2.0-3.0) and performing a repeat TEE to confirm thrombus resolution before attempting another cardioversion. The presence of sludge despite therapeutic rivaroxaban represents a critical failure of thromboembolic prophylaxis in a uniquely high-risk population.
Why This Patient Requires Special Management
ATTR-CA patients with atrial fibrillation face extraordinarily high thrombotic risk that standard risk scores fail to capture. The Canadian Cardiovascular Society explicitly states that cardiac amyloidosis patients are at "particularly high risk of left atrial thrombus and thromboembolic events," with left atrial thrombus reported "in patients receiving therapeutic anticoagulation and in patients in sinus rhythm" 1. Recent data confirms this: a 2025 study found that 20.5% of ATTR-CM patients had definitive or suspected left atrial appendage thrombus at cardioversion, with five patients developing thrombus despite receiving adequate oral anticoagulation for more than three weeks 2.
This is not theoretical—your patient has already demonstrated this phenomenon by developing sludge on rivaroxaban.
The Anticoagulation Strategy
Immediate Action: Switch to Warfarin
While both warfarin and DOACs show similar overall thromboembolic event rates in ATTR-CA populations (0.83% vs 0.67% annually) 3, the presence of sludge despite DOAC therapy represents treatment failure in this individual patient. The 2010 ESC guidelines specifically recommend vitamin K antagonist (VKA) therapy with INR 2.0-3.0 when thrombus is identified on TEE, stating: "VKA (INR 2.0–3.0) is recommended for at least 3 weeks, followed by a repeat TOE to ensure thrombus resolution" 4.
The rationale for warfarin over continuing or switching to another DOAC:
- Established monitoring capability: INR provides objective verification of therapeutic anticoagulation
- Guideline-supported approach: All major guidelines (ESC, AHA/ACC/HRS, CHEST) reference warfarin as the standard for managing detected thrombus 4, 5, 6
- Individual treatment failure: This patient has already failed rivaroxaban prophylaxis
Duration and Monitoring
Maintain warfarin with INR 2.0-3.0 for at least 3 weeks before repeat TEE 4. The ESC guidelines allow for 4-12 weeks if needed for thrombus resolution 6. Given the ATTR-CA context, I would extend to 6-8 weeks before repeat imaging to maximize resolution probability.
The TEE-Guided Approach
Mandatory Repeat TEE
Do not proceed with cardioversion without repeat TEE confirmation of thrombus resolution, regardless of anticoagulation duration. The 2019 AHA/ACC/HRS guidelines support this: "For patients undergoing a TOE-guided strategy in whom thrombus is identified, VKA (INR 2.0–3.0) is recommended for at least 3 weeks, followed by a repeat TOE to ensure thrombus resolution" 5.
The Canadian guidelines specifically emphasize for ATTR-CA: "Transesophageal echocardiography should be considered before cardioversion in stable patients, regardless of duration of arrhythmia or anticoagulation" 1. This recommendation exists precisely because of cases like yours—therapeutic anticoagulation does not reliably prevent thrombus in cardiac amyloidosis.
If Thrombus Persists
If repeat TEE shows persistent thrombus after 6-8 weeks of therapeutic warfarin:
- Continue warfarin and repeat TEE in another 4-6 weeks
- Consider abandoning rhythm control strategy in favor of rate control 4
- The 2010 ESC guidelines state: "If thrombus remains on repeat TOE, an alternative strategy (e.g. rate control) may be considered" 4
If Thrombus Resolves
If repeat TEE confirms resolution:
- Proceed with cardioversion while maintaining therapeutic anticoagulation
- Continue warfarin for at least 4 weeks post-cardioversion 5, 6
- Then continue lifelong anticoagulation based on stroke risk (which is inherently high in ATTR-CA with AF) 1
Long-Term Anticoagulation Strategy
Lifelong Anticoagulation is Mandatory
The Canadian guidelines provide the clearest directive: "In the absence of contraindications, we recommend therapeutic anticoagulation in patients with cardiac amyloidosis and AF, regardless of calculated risk of stroke or systemic embolism" 1. This is a Strong Recommendation with Low-Quality Evidence, reflecting expert consensus that traditional risk scores (CHA₂DS₂-VASc) fail to capture the true thrombotic risk in cardiac amyloidosis.
Warfarin vs. DOAC for Long-Term
After successful cardioversion and the mandatory 4-week post-cardioversion period, you face a decision:
Continue warfarin if:
- Patient can maintain therapeutic INR (TTR ≥65-70%)
- Patient demonstrates good adherence to monitoring
- You want objective verification of anticoagulation status
Consider switching to a different DOAC if:
- Patient achieves excellent medication adherence
- INR control proves difficult (TTR <65%)
- Patient strongly prefers DOAC
The 2026 study comparing warfarin and DOACs in ATTR-CA found no difference in thromboembolic events or major bleeding over 4.3 years 3. However, anticoagulation interruptions >5 days increased thrombotic risk (HR 3.19) 3, emphasizing that consistent therapeutic anticoagulation matters more than the specific agent chosen.
Critical Pitfalls to Avoid
Do Not Proceed with Cardioversion Without Repeat TEE
The 20.5% thrombus rate in ATTR-CM patients at cardioversion 2 makes blind cardioversion unacceptably dangerous, even with prolonged anticoagulation.
Do Not Rely on CHA₂DS₂-VASc Scoring
Traditional stroke risk scores are invalid in cardiac amyloidosis. The Canadian guidelines explicitly state this risk "is not captured by risk scores such as CHADS₆₅ or CHA₂DS₂-VASc" 1.
Do Not Assume 3 Weeks of Anticoagulation is Sufficient
While guidelines specify 3 weeks minimum, ATTR-CA patients may require longer. The detection of sludge in your patient after presumed adequate anticoagulation proves this point.
Monitor for Anticoagulation Gaps
Any interruption in anticoagulation dramatically increases risk 3. Ensure seamless transitions between medications and emphasize adherence.
Rhythm Control vs. Rate Control Consideration
Given the challenges:
- Failed ablation history
- Sludge formation despite anticoagulation
- High AF recurrence rates in ATTR-CA (37.2% at 3 months post-cardioversion) 2
Consider whether rate control might be the more prudent long-term strategy after this cardioversion attempt. The Canadian guidelines note that "the long-term efficacy of rhythm control strategies, including left atrial catheter ablation, is uncertain although might be poor because of diffuse atrial amyloid deposition" 1.
If you proceed with rhythm control, amiodarone is suggested as the best-tolerated antiarrhythmic in cardiac amyloidosis 1, though traditional rate-controlling medications are often poorly tolerated.